ArticleERJ open research2025
Monitoring for paediatric pulmonary graft
Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current diagnostic tests for pulmonary chronic graft Methods: This was a prospective, single-centre cohort study, recruiting children >3 years of age undergoing HSCT between February 2019 and January 2024. MBW and spirometry were performed at regular follow-up visits out to 2 years post-HSCT. Results: 46 children were included in the longitudinal analysis, five (10.9%) of whom developed p-cGvHD. MBW success rate was 93.9% (229 out of 244 visits), compared to 78.3% for spirometry (191 out of 244 visits). In children who developed p-cGvHD, compared to those who did not, peak lung clearance index (LCI) was higher (12.6 Conclusions: MBW is longitudinally feasible in a post-HSCT population as young as 3 years of age. LCI is highly sensitive and specific for p-cGvHD and may help to distinguish different phenotypes of post-HSCT lung disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.